• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Sponsored Post
    • Make a Contribution
    • Technology Job Posting
  • Technology Events 2022-2023
  • Technology Domains
  • Technology Markets
  • Venture Capital
  • Contact
    • About

Genomic Vision Announces a Strategic Partnership With GIPTIS (Genetics Institute for Patients, Therapies, Innovation & Science) Focusing on the Fight Against Genetic Diseases

January 15, 2020 By Technologies.org Leave a Comment

GENOMIC VISION (Paris:GV) (FR0011799907 – GV), a biotechnology company developing Molecular and Artificial Intelligence tools to investigate DNA structural and dynamic changes, in particular in the human genome, is pleased to announce a partnership with GIPTIS, the future Euro Mediterranean Institute founded by Professor Nicolas Lévy, head of the Medical Genetic Department at the renowned hospital of “La Timone” in Marseille. The aim of this partnership is to accelerate and facilitate the diagnosis and treatment of patients, thanks to Genomic Vision proprietary technology and expertise.

In order to improve the management of patients affected by rare genetic diseases, GIPTIS has defined as main objectives to accelerate diagnosis, increase research capacity, multiply the number of effective treatments and improve the care of patients and families.

Professor Nicolas Lévy explains: “Genomic Vision has developed a powerful technology that helps to understand complex genetic abnormalities, in particular in aging and neurological diseases, two therapeutic areas with high unmet clinical needs. It is really helpful in particular to characterize genomic regions with highly repeated sequences for which NGS technologies are not efficient enough.”

Terms of the partnership include several research programs with the development of news assays targeting specific genetic disorders on which Genomic Vision will have exclusive commercialization rights.

Aaron Bensimon, CEO and co-founder of Genomic Vision, adds: “It is the fusion between technological innovation and unmet clinical needs that will cross the frontiers and will bring to the doctors and patients novel tests. Genomic Vision and GIPTIS are the appropriate partners to develop such a novel approach. GIPTIS will bring to GV an important source of unmet medical need in the field of neurological diseases and will be a major asset for the development and validation of these new tests. We are very proud to have been selected by this prestigious institute to participate in this outstanding project. It is not only an opportunity to set-up new IVD assays, but also an opening to Southern markets in which genetic disease rates are higher than elsewhere.”

ABOUT GIPTIS
Today, rare genetic diseases affect 3 million people in France, more than cancer and Alzheimer’s disease combined, and 50 million around the Mediterranean. More than 95% of patients are without adequate treatment and 60% of them are children.

In the majority of cases, these diseases are serious, disabling, chronic and have an impact on entire families.

The aim of GIPTIS: to treat patients better, faster and on a larger scale by facilitating collaborations between the best of the public and private sectors, academic and industrial worlds. GIPTIS unites medical teams, fundamental and applied research teams, start-ups, drug companies and patients associations in the same innovative place of excellence.

GIPTIS faces 4 challenges: accelerate the diagnoses, increase research capacity, multiply the number of effective treatments, improve care for patients and families.

Founded by internationally acclaimed geneticist, Professor Nicolas Lévy, GIPTIS will be a non-profit foundation with mixed governance, for successful cooperation between private and public sectors.

ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing molecular assays and Artificial Intelligence tools to control quality and safety of genetically modified genomes, in particular in genome editing technologies and biomanufacturing processes. These tools are currently use for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Based near Paris, in Bagneux, the Company has approximately 30 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit www.genomicvision.com.

Membre des indices CAC® Mid & Small et CAC® All-Tradable

Related

Filed Under: Tech Tagged With: genome editing technologies

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Research

New skills will be required for the future world of work
A six-step forecasting methodology
APIcoding.com (API coding): Ten API-based project ideas
Web3.ag: Not everyone is happy with decentralization of Internet
Failedeconomies.com (Failed Economies): All governments of failed economies share one common trait – zero tolerance for opposition
52% of retail activities could be automated
Top technology, media, and telecommunications (TMT) companies for total shareholder return (TSR)

Market Analysis

Critical Mineral Shortages Could Disrupt Global Supply Chains
Chocolate grown in a lab
SmartCityMetaverse.com (Smart City Metaverse): Are these the world’s safest cities?
Open Source eCommerce as a Viable Alternative
The semiconductor market is booming
DeFiRetailing.com (DeFi Retailing): DeFi will change retail as we know it
The future belongs to Ethereum app store

Tech Events

Jamstack Conf 2022, November 7-8 2022, San Francisco and online
Photonics Industry Summit, September 21, 2022, Washington, DC
FPGA Conference Europe, July 5 – 7, 2022, NH München Ost Conference Center

Secondary Sidebar

Venture Capital

DefenseStorm Secures $15M in New Financing Round, Including $5M from Community and Mid-Size Bank Venture Fund JAM FINTOP
FreshCut Secures $15M Funding to Accelerate Transformation of Web3 Gaming Content Ecosystem
Fintech Innovator Streetbeat Raises $10M Round, Exceeds 35,000 Clients During One-Month Beta and 125,000 Trading Orders in First Week
Uiflow Secures $5.2 Million in Seed Round to Accelerate Use of No-Code Platform for Enterprises
India’s Cars24 closed a $400 million fundraising round
The Government of Spain adopts the draft Startup Law
Inovia Closes US$325 Million Early-Stage Fund
Razorpay has raised $375M at a valuation of $7.5B
CloudNC raises $45m to deliver autonomous manufacturing
Blockchain co Starkware raises $100m at $8b valuation

Footer

Recent Posts

  • Datadog Launches Audit Trail to Help Businesses Achieve Their Compliance and Governance Objectives
  • Samsung Unveils ISOCELL Image Sensor with Industry’s Smallest 0.56μm Pixel
  • Box Launches Technology Collaboration with FUJIFILM Business Innovation
  • VivaTech, Europe’s number one startup and tech event, makes its big comeback with more than 91,000 participants in Paris
  • Cloudflare Expands Its Zero Trust Platform to Become the Only Cloud-Native Provider with Network Scale
  • New Zealand’s leading port, Ports of Auckland, welcome the world’s first full sized, electric tugboat
  • Energy Dome Successfully Launches First CO2 Battery Long-Duration Energy Storage Plant in the World
  • Resilience Announces $625 Million Series D Financing to Expand Network, Bring Innovative Technologies to Biomanufacturing
  • Apple Unveils M2, Taking the Breakthrough Performance and Capabilities of M1 Even Further
  • The energy in nuclear waste could power the U.S. for 100 years

Media Partners

  • VPNW
  • S3H
  • OPINT
  • Press Media Release
  • OSINT
  • Digital Market
  • Briefly

Media Partners

  • Technology Conferences
  • Event Sharing Network
  • Defense Conferences
  • Cybersecurity Events
  • Event Calendar
  • Calendarial
  • Opinion
  • Venture Capital

Copyright © 2015 Technologies.org

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT